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Abstract
A framework for open discourse on the use of CRISPR-Cas9 technology to manipulate the human 
genome is urgently needed
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Genome engineering technology offers unparalleled potential for modifying human and 
nonhuman genomes. In humans, it holds the promise of curing genetic disease, while in 
other organisms it provides methods to reshape the biosphere for the benefit of the 
environment and human societies. However, with such enormous opportunities come 
unknown risks to human health and well-being. In January, a group of interested 
stakeholders met in Napa, California (1), to discuss the scientific, medical, legal, and ethical 
implications of these new prospects for genome biology. The goal was to initiate an 
informed discussion of the uses of genome engineering technology, and to identify those 
areas where action is essential to prepare for future developments. The meeting identified 
immediate steps to take toward ensuring that the application of genome engineering 
technology is performed safely and ethically.
The promise of so-called “precision medicine” is propelled in part by synergies between two 
powerful technologies: DNA sequencing and genome engineering. Advances in DNA 
sequencing capabilities and genome-wide association studies have provided critical 
information about the genetic changes that influence the development of disease. In the past, 
without the means to make specific and efficient modifications to a genome, the ability to 
act on this information was limited. However, this limitation has been upended by the rapid 
development and widespread adoption of a simple, inexpensive, and remarkably effective 
genome engineering method known as clustered regularly interspaced short palindromic 
repeats (CRISPR)–Cas9 (2). Building on predecessor platforms, a rapidly expanding family 
of CRISPR-Cas9–derived technologies is revolutionizing the fields of genetics and 
molecular biology as researchers employ these methods to change DNA sequences—by 
introducing or correcting genetic mutations—in a wide variety of cells and organisms.
CURRENT APPLICATIONS
The simplicity of the CRISPR-Cas9 system allows any researcher with knowledge of 
molecular biology to modify genomes, making feasible experiments that were previously 
difficult or impossible to conduct. For example, the CRISPR-Cas9 system enables 
introduction of DNA sequence changes that correct genetic defects in whole animals, such 
as replacing a mutated gene underlying liver-based metabolic disease in a mouse model (3). 
The technique also allows DNA sequence changes in pluripotent embryonic stem cells (4) 
that can then be cultured to produce specific tissues, such as cardiomyocytes or neurons (5). 
Such studies are laying the groundwork for refined approaches that could eventually treat 
human disease. CRISPR-Cas9 technology can also be used to replicate precisely the genetic 
basis for human diseases in model organisms, leading to unprecedented insights into 
previously enigmatic disorders.
In addition to facilitating changes in differentiated somatic cells of animals and plants, 
CRISPR-Cas9 technology as well as other genome engineering methods can be used to 
change the DNA in the nuclei of reproductive cells that transmit information from one 
generation to the next (an organism’s “germ line”). Thus, it is now possible to carry out 
genome modification in fertilized animal eggs or embryos, thereby altering the genetic 
makeup of every differentiated cell in an organism and so ensuring that the changes will be 
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passed on to the organism’s progeny. Humans are no exception—changes to the human 
germ line could be made using this simple and widely available technology.
MOVING FORWARD
Given these rapid developments, it would be wise to begin a discussion that bridges the 
research community, relevant industries, medical centers, regulatory bodies, and the public 
to explore responsible uses of this technology. To initiate this conversation, developers and 
users of the CRISPR-Cas9 technology, and experts in genetics, law, and bioethics, discussed 
the implications and rapid expansion of the genome engineering field (1). This group, all 
from the United States, and which included some of the leaders in the original 1970s 
discussions about recombinant DNA research at Asilomar and elsewhere, focused on the 
issue of human germline engineering, as the methods have already been demonstrated in 
mice (6) and monkeys (7). The Napa discussion did not address mitochondrial transfer (8, 
9), a technique that does not use CRISPR-Cas9. Although characterized by some as another 
form of “germline” engineering, mitochondrial transfer raises different issues and has 
already been approved by the Human Fertilisation and Embryology Authority and by 
Parliament in the United Kingdom (10) and is being considered by the Institute of Medicine 
and the Food and Drug Administration in the United States (11). At the Napa meeting, 
“genome modification” and “germline engineering” referred to changes in the DNA of the 
nucleus of a germ cell.
The possibility of human germline engineering has long been a source of excitement and 
unease among the general public, especially in light of concerns about initiating a “slippery 
slope” from disease-curing applications toward uses with less compelling or even troubling 
implications. Assuming the safety and efficacy of the technology can be ensured, a key point 
of discussion is whether the treatment or cure of severe diseases in humans would be a 
responsible use of genome engineering, and if so, under what circumstances. For example, 
would it be appropriate to use the technology to change a disease-causing genetic mutation 
to a sequence more typical among healthy people? Even this seemingly straightforward 
scenario raises serious concerns, including the potential for unintended consequences of 
heritable germline modifications, because there are limits to our knowledge of human 
genetics, gene-environment interactions, and the pathways of disease (including the 
interplay between one disease and other conditions or diseases in the same patient). In the 
United States, such human research currently would require an Investigational New Drug 
exemption from the Food and Drug Administration, but value judgments about the balance 
between actions in the present and consequences in the future need deeper consideration of 
the ethical implications of human germline genome editing than the Investigational New 
Drug process provides.
RECOMMENDATIONS
To better inform future public conversations recommended by the Napa meeting, research is 
needed to understand and manage risks arising from the use of the CRISPR-Cas9 
technology. Considerations include the possibility of off-target alterations, as well as on-
target events that have unintended consequences. It is critical to implement appropriate and 
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standardized benchmarking methods to determine the frequency of off-target effects and to 
assess the physiology of cells and tissues that have undergone genome editing. At present, 
the potential safety and efficacy issues arising from the use of this technology must be 
thoroughly investigated and understood before any attempts at human engineering are 
sanctioned, if ever, for clinical testing. As with any therapeutic strategy, higher risks can be 
tolerated when the reward of success is high, but such risks also demand higher confidence 
in their likely efficacy. And, for countries whose regulatory agencies focus on safety and 
efficacy but not on broader social and ethical concerns, another venue is needed to facilitate 
public conversation.
Given the speed with which the genome engineering field is evolving, the Napa meeting 
concluded that there is an urgent need for open discussion of the merits and risks of human 
genome modification by a broad cohort of scientists, clinicians, social scientists, the general 
public, and relevant public entities and interest groups.
In the near term, we recommend that steps be taken to:
1. Strongly discourage, even in those countries with lax jurisdictions where it might 
be permitted, any attempts at germline genome modification for clinical application 
in humans, while societal, environmental, and ethical implications of such activity 
are discussed among scientific and governmental organizations. (In countries with a 
highly developed bioscience capacity, germline genome modification in humans is 
currently illegal or tightly regulated.) This will enable pathways to responsible uses 
of this technology, if any, to be identified.
2. Create forums in which experts from the scientific and bioethics communities can 
provide information and education about this new era of human biology, the issues 
accompanying the risks and rewards of using such powerful technology for a wide 
variety of applications including the potential to treat or cure human genetic 
disease, and the attendant ethical, social, and legal implications of genome 
modification.
3. Encourage and support transparent research to evaluate the efficacy and specificity 
of CRISPR-Cas9 genome engineering technology in human and nonhuman model 
systems relevant to its potential applications for germline gene therapy. Such 
research is essential to inform deliberations about what clinical applications, if any, 
might in the future be deemed permissible.
4. Convene a globally representative group of developers and users of genome 
engineering technology and experts in genetics, law, and bioethics, as well as 
members of the scientific community, the public, and relevant government agencies 
and interest groups—to further consider these important issues, and where 
appropriate, recommend policies.
CONCLUSIONS
At the dawn of the recombinant DNA era, the most important lesson learned was that public 
trust in science ultimately begins with and requires ongoing transparency and open 
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discussion. That lesson is amplified today with the emergence of CRISPR-Cas9 technology 
and the imminent prospects for genome engineering. Initiating these fascinating and 
challenging discussions now will optimize the decisions society will make at the advent of a 
new era in biology and genetics.
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